Page last updated: 2024-08-26

fulvestrant and azd9496

fulvestrant has been researched along with azd9496 in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (42.86)	24.3611
2020's	4 (57.14)	2.80

Authors

Authors	Studies
Andrews, DM; Ballard, P; Bradbury, RH; Buttar, D; Callis, RJ; Currie, GS; Curwen, JO; Davies, CD; de Almeida, C; De Savi, C; Donald, CS; Feron, LJ; Gingell, H; Glossop, SC; Hayter, BR; Hussain, S; Karoutchi, G; Lamont, SG; MacFaul, P; Moss, TA; Norman, RA; Pearson, SE; Rabow, AA; Tonge, M; Walker, GE; Weir, HM; Wilson, Z	1
Baselga, J; Carlson, KE; Chandarlapaty, S; De Stanchina, E; Fanning, S; Goeppert, AU; Greene, G; Katzenellenbogen, JA; Lawson, M; Li, Z; Martin, TS; Mazzola, AM; Morrow, C; Razavi, P; Smith, A; Toy, W; Uddin, S; Weir, H; Wilson, J; Wong, WL	1
Brown, H; Cataldo, ML; Chamness, GC; De Angelis, C; Delpuech, O; Fu, X; Hilsenbeck, SG; Jeselsohn, R; Mitchell, T; Nagi, C; Nardone, A; Osborne, CK; Pilling, M; Rimawi, MF; Schiff, R; Shea, MJ; Trivedi, M; Veeraraghavan, J; Weir, H	1
Carroll, D; Cheung, KL; Dixon, JM; Evans, A; Fasching, PA; Harbeck, N; Henschen, S; Jahan, A; Kenny, LM; Kirwan, CC; Klinowska, T; Kothari, A; Lindemann, JPO; MacDonald, A; Mather, R; Maudsley, R; Mohamed, O; Moschetta, M; Nikolaou, M; Robertson, JFR; Roudier, MP; Sarvotham, T; Schiavon, G; Schmid, P; Wuerstlein, R; Zhou, D; Zhou, L	1
Cornella-Taracido, I; Garcia-Echeverria, C	1
Goloubeva, O; Kazi, A; Sabnis, GJ; Schech, A; Yu, S	1
Cong, H; Li, D; Liu, J; Lu, Y; Tian, W; Wei, A; Yang, L; Zhuo, Y	1

Reviews

1 review(s) available for fulvestrant and azd9496

Article	Year
Monovalent protein-degraders - Insights and future perspectives. Bioorganic & medicinal chemistry letters, 2020, 06-15, Volume: 30, Issue:12 Topics: Biosensing Techniques; Cinnamates; Drug Discovery; Fulvestrant; Humans; Indoles; Ligands; Protein Binding; Proteolysis; Receptors, Estrogen; Stilbenes; Tamoxifen; Ubiquitin-Protein Ligases	2020

Trials

1 trial(s) available for fulvestrant and azd9496

Article	Year
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-15, Volume: 26, Issue:16 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Cinnamates; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Middle Aged; Receptor, ErbB-2; Receptors, Progesterone	2020

Article

Year

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER

Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-15, Volume: 26, Issue:16

Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Cinnamates; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Middle Aged; Receptor, ErbB-2; Receptors, Progesterone

2020

Other Studies

5 other study(ies) available for fulvestrant and azd9496

Article	Year
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu Journal of medicinal chemistry, 2015, Oct-22, Volume: 58, Issue:20 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cinnamates; Clinical Trials, Phase I as Topic; Down-Regulation; Drug Design; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Indoles; Injections, Intramuscular; X-Ray Diffraction	2015
Activating Cancer discovery, 2017, Volume: 7, Issue:3 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cinnamates; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Indoles; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Domains; Xenograft Model Antitumor Assays	2017
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. British journal of cancer, 2019, Volume: 120, Issue:3 Topics: Animals; Breast Neoplasms; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Heterografts; Humans; Indoles; MCF-7 Cells; Mice; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen	2019
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity. The Journal of steroid biochemistry and molecular biology, 2020, Volume: 202 Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cinnamates; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Indoles; Mammary Neoplasms, Experimental; Mice, Nude; Postmenopause; Selective Estrogen Receptor Modulators	2020
Syringaresinol attenuates sepsis-induced cardiac dysfunction by inhibiting inflammation and pyroptosis in mice. European journal of pharmacology, 2021, Dec-15, Volume: 913 Topics: Animals; Cardiotonic Agents; Cinnamates; Disease Models, Animal; Fulvestrant; Furans; Heart; Heart Diseases; Humans; Indoles; Inflammation; Lignans; Male; Mice; Molecular Docking Simulation; Myocardium; Pyroptosis; Receptors, Estrogen; Sepsis; Sirtuin 1	2021